The most common mistake in EDC selection is starting with a feature comparison. A product with 40 checked boxes is not a better choice than one with 28 — because studies and organizations differ dramatically in phase, scale, regulatory posture, funding, integration needs, and the people available to build and run the system.

Write requirements before you watch demos

A demo is a persuasion event. Walking into one without written requirements means the vendor's script becomes your evaluation framework. Before any demo, document:

  1. The studies. How many studies per year, of what type — interventional trials, observational cohorts, registries? Single-site or multi-site? How many participants and data points, roughly?
  2. The regulatory posture. Will any study support an FDA submission or run under an IND/IDE? Are you subject to 21 CFR Part 11 [1], EU requirements, or "only" the Common Rule and institutional policy? This single answer changes the shortlist more than any feature.
  3. The data sources. Site-entered forms only, or also participant-reported outcomes, laboratory data, imaging and device data, and EHR integration?
  4. The people. Who will design forms, write edit checks, manage queries, and administer accounts? A dedicated data management team and a part-time coordinator need different systems.
  5. The lifespan. One study, or a portfolio? A system chosen for a single trial and a system chosen as institutional infrastructure are different decisions (multi-study management).

The first decision: which kind of system

Before comparing products, decide which of the six primary-function categories you are actually shopping in. We describe these fully in our technology landscape; in brief:

  • Study-Specific EDC — built, validated, and run per study.
  • Institutional Research Platform — one installation serving many studies across an institution.
  • Clinical Trial Operations Suite — broader operational tooling in which data capture is one module among several.
  • Participant Data Collection — eCOA, ePRO, eConsent, wearables, and decentralized-trial tools that collect data directly from participants.
  • Research Data Platform — aggregation, standardization, and delivery of research data across sources.
  • Configurable Application Platform — general-purpose form and workflow platforms adapted to research use.

These are descriptive categories, not a ranking, and many products serve more than one. But most failed selections we hear about are category errors: an academic group licensing a per-study commercial EDC when it needed institutional infrastructure, or a sponsor stretching a lightweight survey platform into a regulated trial. Our companion guide, REDCap, Commercial EDC, or Configurable Research Platform?, works through the most common version of this decision.

Evaluate against capabilities, not adjectives

Vendor materials describe products in adjectives; requirements should be written in capabilities. Our capability reference defines each one in plain language. For most EDC selections, the load-bearing capabilities are:

Weight these by your requirements document — a registry cares more about longitudinal follow-up than about randomization; a phase III trial reverses that.

Regulatory considerations

If a study is subject to FDA regulation, the electronic records and signatures in your EDC fall under 21 CFR Part 11 [1], and FDA's 2023 guidance on electronic systems in clinical investigations describes how the agency currently thinks about such systems, including cloud services [2]. ICH E6(R3) adds sponsor-level expectations for computerized systems, data governance, and traceability [3]. Three practical consequences:

  • "Part 11 compliant" is a shorthand, not a certificate. No agency certifies products. A vendor can supply compliant capabilities — audit trails, access controls, signature manifests — but compliance is a property of your implementation and procedures, not the license. See our full discussion in 21 CFR Part 11.
  • Validation is partly your job. Vendors validate their platform; you (or your CRO) must still validate your study build — and keep the validation documentation that proves it [3][4].
  • Not every study needs the same rigor. A non-regulated observational study has real obligations — consent, privacy, data integrity — but paying for submission-grade infrastructure it will never use is a cost, not a virtue. Match rigor to the study, deliberately and in writing.

Total cost beyond the license

Published prices rarely represent total cost. Depending on the system and category, the full cost may include:

  • licenses or per-study fees
  • study build and configuration services
  • validation and documentation effort
  • hosting and environment fees
  • integrations with labs, safety, CTMS, and EHR systems
  • randomization and coding modules priced separately
  • training for site staff, coordinators, and data managers
  • help-desk and support tiers
  • mid-study change fees
  • data export, archiving, and — importantly — decommissioning at study end

Questions to ask vendors

  • Which of your customers look like us — same study types, scale, and regulatory posture — and can we speak with two of them?
  • What exactly is included in the quoted price, and what is a change order?
  • How are mid-study amendments handled, technically and commercially?
  • What validation documentation do you provide, and what remains our responsibility?
  • What are your standard data export formats, and is the full audit trail exportable?
  • What happens to our data at contract end, in what format, at what cost?
  • What is your uptime history and support model during our sites' working hours, in their time zones and languages?
  • Which functions are native, and which are partner products under your brand?

Red flags

  • Reluctance to put pricing, export formats, or exit terms in writing.
  • "Fully Part 11 certified" as a selling point — no such certification exists [1][2].
  • Demos that cannot deviate from the script when you pose your own study.
  • No reference customers of your type — a vendor superb at phase III pharma trials may have never supported an investigator-initiated academic study, and vice versa.
  • Vague answers about what a mid-study form change does to already-entered data.
  • Promotional pressure keyed to your grant or study start date.

Academic and industry procurement differ

Industry sponsors typically select EDC per study or per portfolio, often through a CRO, with procurement, quality, and legal review built into the process. Academic selection runs differently: grant budgets are fixed before the system is chosen, institutional review (security, privacy, sometimes a systems office) adds its own timeline, and many institutions already operate REDCap — developed at Vanderbilt precisely for institutionally supported academic data capture [5] — which makes the real question "when do we go beyond the institutional platform?" rather than "which EDC do we buy?" Commercial options in this market include, among others, Castor, Medidata Rave, Medrio, OpenClinica, Oracle Clinical One, QuesGen, REDCap Cloud, Veeva Clinical Data, and Zelta; our technology directory records what we have verified about each, and Academic vs. Commercial Clinical Research examines how the two worlds shape decisions like this one.

Where to go next

Start with the requirements document — it is the artifact everything else in this guide depends on. Then use the technology landscape to pick your category, the capability reference to structure your evaluation, and EDC, CTMS, eCOA, eConsent, and eTMF to keep the surrounding systems straight. Classification on this site is descriptive research with evidence behind it — never a ranking, and never paid placement.